Cancer Survivorship: ImpediMed SOZO Device Improves Detection and Monitoring of Lymphedema for Breast Cancer Patients
BRISBANE, Australia & CARLSBAD, Calif.--(BUSINESS WIRE)--Oct 11, 2018--In recognition of October as Breast Cancer Awareness Month, ImpediMed Limited (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), calls for increased utilization of the SOZO device for early detection of conditions resulting from the sometimes destructive effects of cancer treatments. Acknowledging that as many as 65 percent of the 250,000 women diagnosed with breast cancer annually may develop chronic, irreversible lymphedema, the latest FDA-cleared BIS platform from ImpediMed, provides a critical tool immediately upon cancer diagnosis to measure, monitor and possibly reverse conditions such as lymphedema.
Chirag Shah, M.D., staff, Department of Radiation Oncology, and Director, Clinical Research, Department of Radiation Oncology, Cleveland Clinic, says, “While cancer treatments and the resulting side effects can have long-term implications on a patient’s health and quality of life, conditions such as lymphedema can be monitored for, and even reversed, with better, more detailed information regarding fluid and tissue status that allows for early intervention. SOZO technology provides easy access to this level of information and data without the need for an invasive procedure. When these conditions are caught early, intervention and prevention are possible.”
Important facts about breast cancer-related conditions include:Breast cancer-related lymphedema (BCRL) is a secondary disease caused by cancer or its treatment. Studies show that ImpediMed’s patented BIS technology enables healthcare providers to clinically assess a patient and detect lymphedema as much as 4-10 months earlier than other methods. Lymphedema is now a separate category in the NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) for Survivorship, and cancer survivorship is now a requirement for the accreditation guidelines issued by the National Accreditation Program For Breast Centers ( NAPBC ). The Oncology Section of the American Physical Therapy Association ( APTA ) has also issued new guidelines to aid clinicians in diagnosing secondary BCRL. Between 30-87 percent of cancer patients are diagnosed with malnutrition, and 30-60 percent are re-diagnosed with protein-calorie malnutrition. Over 95 percent of cancer patients indicate one or more symptoms involving the gastrointestinal (GI) tract contributing to compromised nutritional status, including insufficient energy intake, weight loss, loss of muscle mass, loss of subcutaneous fat, localized or generalized fluid accumulation that could mask weight loss, and diminished functional status. The field of cardio-oncology has emerged to address resulting HF from chemotherapy drugs and radiation as a side effect in late stage cancer survivors. BIS may prove to be a useful adjunct in the management of HF, detecting extracellular fluid excess and impending HF decompensation before hospitalization and correlating well with diastolic pulmonary artery pressures.
Richard Carreon, managing director and CEO, ImpediMed, says, “Breast Cancer Awareness Month reaffirms our commitment to cancer survivors. We are dedicated to providing solutions that help to improve the quality of life for those who are undergoing cancer treatment.”
Carreon also points to the value of SOZO to the nation’s health plans, ACOs and other payer/provider organizations, adding, “Demonstrated results show a statistically significant reduction in rates of clinical lymphedema, lower costs and better quality of life for patients. Utilization of this technology will impact risk stratification in ways that can positively impact population health management programs.”
Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO ® for multiple indications including heart failure and lymphoedema, sold in select markets globally. Visit www.impedimed.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181011005133/en/
CONTACT: For ImpediMed
Laura Carabello, 201-641-1911 x12
KEYWORD: AUSTRALIA UNITED STATES NORTH AMERICA AUSTRALIA/OCEANIA CALIFORNIA
INDUSTRY KEYWORD: HEALTH CARDIOLOGY HOSPITALS MEDICAL DEVICES ONCOLOGY OTHER HEALTH FDA
SOURCE: ImpediMed Limited
Copyright Business Wire 2018.
PUB: 10/11/2018 09:00 AM/DISC: 10/11/2018 09:01 AM